[11]
|
Rockhill
|
2001
|
America
|
Cohort
|
2
|
5
|
82,109
|
45–71
|
Nurses’ Health Study (NHS)
|
General population
|
1992–1997
|
5.0
|
0.58 (0.56–0.60)
|
[30]
|
Amir
|
2003
|
United Kingdom
|
Cohort
|
2
|
10
|
3150
|
21–73
|
Women attending the Family History Screening Programme in University Hospital of South Manchester
|
Not defined
|
1987–2001
|
5.0
|
0.74 (0.67–0.80)
|
[21]
|
Tice
|
2005
|
America
|
Cohort
|
2
|
5
|
81,777
|
55.9
|
Community-based registry San Francisco Mammography Registry (SFMR)
|
General population
|
1993–2002
|
5.1 (0.1–15)
|
0.67 (0.65–0.68)
|
[29]
|
Decarli
|
2006
|
Italy
|
Cohort
|
2
|
5
|
10,031
|
35–64
|
Florence—European Prospective Investigation Into Cancer and Nutrition cohort (EPIC)
|
General population
|
1993–2002
|
9.0
|
0.59 (0.55–0.63)
|
[36]
|
Crispo
|
2008
|
Italy
|
Case–control
|
1
|
5
|
1765
|
53.7
|
National Cancer Institute of Naples (southern Italy)
|
NA
|
1997–2000
|
NA
|
0.55 (0.53–0.58)
|
[15]
|
Tice
|
2008
|
America
|
Cohort
|
2
|
5
|
251,789
|
40–74
|
National Cancer Institute-funded Breast Cancer Surveillance Consortium (BCSC)
|
General population
|
since 1994
|
5.3
|
0.61 (0.60–0.62)
|
[42]
|
Pan
|
2009
|
China
|
Cross-sectional
|
1
|
5
|
2133
|
> 35
|
Breast cancer risk assessment, evaluation and health education program, in Beijing and Guangzhou community
|
NA
|
2006–2007
|
NA
|
0.64 (0.61–0.67)
|
[43]
|
Liu
|
2010
|
China
|
Cross-sectional
|
2
|
5
|
246
|
49.82
|
High-risk breast cancer screening model and chemical intervention study at the community level
|
NA
|
2007–2009
|
NA
|
0.56 (0.49–0.64)
|
[44]
|
Wang
|
2010
|
China
|
Case–control
|
1
|
5
|
228
|
32–75
|
Shenzhou Hospital of Shenyang Medical College-based breast cancer cases and control
|
NA
|
1998–2007
|
NA
|
0.93 (0.89–0.97)
|
[17]
|
Tarabishy
|
2011
|
America
|
Cohort
|
2
|
5
|
4726
|
18–85
|
Mayo Benign Breast Disease (BBD)
|
High risk
|
1982–1991
|
16.2
|
0.64 (0.62–0.66)
|
[22]
|
Vacek
|
2011
|
America
|
Cohort
|
1
|
5
|
19,779
|
> 70
|
Vermont Breast Cancer Surveillance System (VBCSS)
|
High risk
|
2001–2009
|
7.1
|
0.54 (0.52–0.56)
|
[27]
|
Banegas
|
2012
|
America
|
Cohort
|
2
|
5
|
128,976
|
63.51
|
Women’s Health Initiative (WHI)
|
General population
|
1993–2005
|
5.0
|
0.58 (0.57–0.59)
|
[23]
|
Quante
|
2012
|
America
|
Cohort
|
2
|
10
|
1857
|
44
|
Women with high risk for breast or ovarian cancer in New York site of the Breast Cancer Family Registry (BCFR)
|
High risk
|
1995–2011
|
8.1
|
0.63 (0.58–0.69)
|
[32]
|
Pastor-Barriuso
|
2013
|
Spain
|
Cohort
|
2
|
5
|
54,649
|
45–68
|
Population-based Navarre Breast Cancer Screening Program (NBCSP)
|
General population
|
1996–2005
|
7.7
|
0.54 (0.52–0.57)
|
[51]
|
Dite
|
2013
|
Australia
|
Case–control
|
2
|
5
|
1425
|
45.4
|
Cases and controls from the Australian Breast Cancer Family Registry (ABCFR)
|
NA
|
1992–1998
|
NA
|
0.58 (0.55–0.61)
|
[40]
|
Anothaisintawee
|
2013
|
Thailand
|
Cross-sectional
|
NA
|
NA
|
15,718
|
NA
|
Ramathibodi Hospital and two tertiary hospitals
|
NA
|
2011–2013
|
NA
|
0.41 (0.36–0.46)
|
[24]
|
Ronser
|
2013
|
America
|
Cohort
|
2
|
5
|
11,419
|
54.0 ± 3.3
|
Postmenopausal women in California Teachers Study (CTS)
|
High risk
|
1995–2009
|
5.0
|
0.55 (0.53–0.56)
|
[41]
|
Min-1
|
2014
|
Korea
|
Cohort
|
2
|
5
|
40,229
|
> 10
|
Breast cancer screening patients routinely screened in Women’s Healthcare Center of Cheil General Hospital
|
Not defined
|
1999–2004
|
5
|
0.55 (0.50–0.59)
|
[41]
|
Min-2
|
2014
|
Korea
|
Cohort
|
3
|
5
|
40,229
|
> 10
|
Breast cancer screening patients routinely screened in Women’s Healthcare Center of Cheil General Hospital
|
Not defined
|
1999–2004
|
5
|
0.54 (0.50–0.59)
|
[18]
|
Powell
|
2014
|
America
|
Cohort
|
2
|
5
|
12,843
|
NA
|
Marin Women’s Study with high rate of breast cancer, null parity and delayed childbirth
|
High risk
|
2003–2007
|
7.7
|
0.62 (0.59–0.66)
|
[45]
|
Duan
|
2014
|
China
|
Case–control
|
2
|
5
|
400
|
35–74
|
Breast cancer cases and controls in the First Affiliate Hospital of KunMing Medical University
|
NA
|
2007–2011
|
NA
|
0.54 (0.49–0.60)
|
[19]
|
McCarthy
|
2015
|
America
|
Cohort
|
2
|
5
|
464
|
48.7 ± 13
|
Women referred for biopsy with abnormal (Breast Imaging Reporting And Data System, BI-RADS 4) mammograms at the Hospital of the University of Pennsylvania
|
High risk
|
2003–2012
|
5.0
|
0.71 (0.65–0.78)
|
[34]
|
Dartois-1
|
2015
|
France
|
Cohort
|
2
|
5
|
5843
|
42–72
|
Premenopausal Women in French E3N (E´ tude E´ pide´miologique aupre`s des femmes de laMutuelle Ge´ne´rale de l’E´ ducation Nationale (MGEN)) prospective cohort to investigate the cancer risk factors
|
General population
|
1993–1998
|
5.0
|
0.61 (0.55–0.68)
|
[34]
|
Dartois-2
|
2015
|
France
|
Cohort
|
2
|
5
|
7331
|
42–72
|
Postmenopausal Women in French E3N (E´ tude E´ pide´miologique aupre`s des femmes de laMutuelle Ge´ne´rale de l’E´ ducation Nationale (MGEN)) prospective cohort to investigate the cancer risk factors
|
High risk
|
1993–1998
|
14.0
|
0.55 (0.50–0.60)
|
[39]
|
Hu
|
2015
|
China
|
Cohort
|
2
|
5
|
42,908
|
35–69
|
Women participated in the breast cancer screening in Zhejiang eastern coastal areas of China
|
General population
|
2008–2014
|
5.0
|
0.59 (0.47–0.70)
|
[35]
|
Brentnall
|
2015
|
United Kingdom
|
Cohort
|
2
|
10
|
50,628
|
47–73
|
15 screening areas in Greater Manchester, UK
|
General population
|
2009–2014
|
3.2
|
0.54 (0.52–0.56)
|
[20]
|
Schonberg-1
|
2015
|
America
|
Cohort
|
2
|
5
|
71,293
|
70.0 ± 7.0
|
Nurses’ Health Study (NHS)
|
High risk
|
2004–2009
|
5.0
|
0.57 (0.55–0.58)
|
[20]
|
Schonberg-2
|
2015
|
America
|
Cohort
|
2
|
5
|
79,611
|
71.0 ± 6.8
|
Women’s Health Initiative (WHI), extensive study
|
High risk
|
2005–2010
|
5.0
|
0.58 (0.56–0.59)
|
[46]
|
Rong
|
2016
|
China
|
Case–control
|
1
|
5
|
816
|
48.9
|
Breast cancer cases and controls in the Shenzhen Maternal and Child Health Care hospital
|
NA
|
2011–2013
|
NA
|
0.69 (0.68–0.71)
|